A citation-based method for searching scientific literature

A Gringeri, B Lundin, S von Mackensen, L Mantovani, P M Mannucci. J Thromb Haemost 2011
Times Cited: 331







List of co-cited articles
678 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J Manco-Johnson, Thomas C Abshire, Amy D Shapiro, Brenda Riske, Michele R Hacker, Ray Kilcoyne, J David Ingram, Michael L Manco-Johnson, Sharon Funk, Linda Jacobson,[...]. N Engl J Med 2007
91

Guidelines for the management of hemophilia.
A Srivastava, A K Brewer, E P Mauser-Bunschoten, N S Key, S Kitchen, A Llinas, C A Ludlam, J N Mahlangu, K Mulder, M C Poon,[...]. Haemophilia 2013
44

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
L A Valentino, V Mamonov, A Hellmann, D V Quon, A Chybicka, P Schroth, L Patrone, W-Y Wong. J Thromb Haemost 2012
191
32

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, Pratima Chowdary, Neil C Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty,[...]. Blood 2014
308
26

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Johannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse-Jarres, Claude Negrier, Craig Kessler,[...]. N Engl J Med 2017
466
25

Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Annarita Tagliaferri, Giulio Feola, Angelo Claudio Molinari, Cristina Santoro, Gianna Franca Rivolta, Dorina Bianca Cultrera, Fabio Gagliano, Ezio Zanon, Maria Elisa Mancuso, Lelia Valdré,[...]. Thromb Haemost 2015
70
32

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
M J Manco-Johnson, C L Kempton, M T Reding, T Lissitchkov, S Goranov, L Gercheva, L Rusen, M Ghinea, V Uscatescu, V Rescia,[...]. J Thromb Haemost 2013
135
22

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, M Elisa Mancuso, Christophe Schmitt, Victor Jiménez-Yuste, Christine Kempton, Christophe Dhalluin,[...]. N Engl J Med 2018
282
22

Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
M J Manco-Johnson, B Lundin, S Funk, C Peterfy, D Raunig, M Werk, C L Kempton, M T Reding, S Goranov, L Gercheva,[...]. J Thromb Haemost 2017
63
34


Definitions in hemophilia: communication from the SSC of the ISTH.
V S Blanchette, N S Key, L R Ljung, M J Manco-Johnson, H M van den Berg, A Srivastava. J Thromb Haemost 2014
332
20


Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Barbara A Konkle, Oleksandra Stasyshyn, Pratima Chowdary, David H Bevan, Tim Mant, Midori Shima, Werner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone,[...]. Blood 2015
156
20

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
P W Collins, V S Blanchette, K Fischer, S Björkman, M Oh, S Fritsch, P Schroth, G Spotts, J Astermark, B Ewenstein. J Thromb Haemost 2009
242
19

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
I M Nilsson, E Berntorp, T Löfqvist, H Pettersson. J Intern Med 1992
741
18

Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
M T Reding, H J Ng, L H Poulsen, M E Eyster, I Pabinger, H-J Shin, R Walsch, M Lederman, M Wang, M Hardtke,[...]. J Thromb Haemost 2017
68
22


Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
G Young, J Mahlangu, R Kulkarni, B Nolan, R Liesner, J Pasi, C Barnes, S Neelakantan, G Gambino, L M Cristiano,[...]. J Thromb Haemost 2015
108
14

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
K John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann,[...]. N Engl J Med 2017
191
13

Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Alfonso Iorio, Emanuela Marchesini, Maura Marcucci, Kent Stobart, Anthony Kc Chan. Cochrane Database Syst Rev 2011
120
13

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Flora Peyvandi, Pier M Mannucci, Isabella Garagiola, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Suresh Hanagavadi, Ramabadran Varadarajan, Mehran Karimi,[...]. N Engl J Med 2016
276
13

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Paul Giangrande, Tatiana Andreeva, Pratima Chowdary, Silke Ehrenforth, Hideji Hanabusa, Frank W G Leebeek, Steven R Lentz, Laszlo Nemes, Lone Hvitfeldt Poulsen, Elena Santagostino,[...]. Thromb Haemost 2017
67
19


The hemophilias--from royal genes to gene therapy.
P M Mannucci, E G Tuddenham. N Engl J Med 2001
675
12

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Jerry S Powell, K John Pasi, Margaret V Ragni, Margareth C Ozelo, Leonard A Valentino, Johnny N Mahlangu, Neil C Josephson, David Perry, Marilyn J Manco-Johnson, Shashikant Apte,[...]. N Engl J Med 2013
232
12

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami. N Engl J Med 2016
241
12

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Peter W Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gürsel, Johnny Mahlangu, Tadashi Matsushita, Eveline P Mauser-Bunschoten,[...]. Blood 2014
117
12

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
L A Valentino, S W Pipe, P W Collins, V S Blanchette, E Berntorp, K Fischer, B M Ewenstein, M Oh, G Spotts. Haemophilia 2016
43
27

WFH Guidelines for the Management of Hemophilia, 3rd edition.
Alok Srivastava, Elena Santagostino, Alison Dougall, Steve Kitchen, Megan Sutherland, Steven W Pipe, Manuel Carcao, Johnny Mahlangu, Margaret V Ragni, Jerzy Windyga,[...]. Haemophilia 2020
282
12

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F Pierce, Wing Y Wong,[...]. N Engl J Med 2017
348
11

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
P Chowdary, S Lethagen, U Friedrich, B Brand, C Hay, F Abdul Karim, R Klamroth, P Knoebl, M Laffan, J Mahlangu,[...]. J Thromb Haemost 2015
154
11


Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
Sarah C Darby, Sau Wan Kan, Rosemary J Spooner, Paul L F Giangrande, Frank G H Hill, Charles R M Hay, Christine A Lee, Christopher A Ludlam, Michael Williams. Blood 2007
353
11

Defining extended half-life rFVIII-A critical review of the evidence.
J Mahlangu, G Young, C Hermans, V Blanchette, E Berntorp, E Santagostino. Haemophilia 2018
42
26

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
B Nolan, J Mahlangu, D Perry, G Young, R Liesner, B Konkle, S Rangarajan, S Brown, H Hanabusa, K J Pasi,[...]. Haemophilia 2016
56
19

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
P Collins, E Chalmers, P Chowdary, D Keeling, M Mathias, J O'Donnell, K J Pasi, S Rangarajan, A Thomas. Haemophilia 2016
77
12

Treatment adherence in hemophilia.
Courtney D Thornburg, Natalie A Duncan. Patient Prefer Adherence 2017
63
15


Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
A Iorio, E Iserman, V Blanchette, G Dolan, C Escuriola Ettingshausen, C Hermans, C Negrier, J Oldenburg, A Reininger, C Rodriguez-Merchan,[...]. Haemophilia 2017
42
23

Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
S von Mackensen, W Kalnins, J Krucker, J Weiss, W Miesbach, M Albisetti, I Pabinger, J Oldenburg. Haemophilia 2017
35
28

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
E S Mullins, O Stasyshyn, M T Alvarez-Román, D Osman, R Liesner, W Engl, M Sharkhawy, B E Abbuehl. Haemophilia 2017
44
22

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Jerry S Powell, Neil C Josephson, Doris Quon, Margaret V Ragni, Gregory Cheng, Ella Li, Haiyan Jiang, Lian Li, Jennifer A Dumont, Jaya Goyal,[...]. Blood 2012
157
10

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidziak,[...]. Lancet Haematol 2019
131
10

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
P W Collins, K Fischer, M Morfini, V S Blanchette, S Björkman. Haemophilia 2011
153
9

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.
Kathelijn Fischer, Katarina Steen Carlsson, Pia Petrini, Margareta Holmström, Rolf Ljung, H Marijke van den Berg, Erik Berntorp. Blood 2013
150
9

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
B M Feldman, M Pai, G E Rivard, S Israels, M-C Poon, C Demers, S Robinson, K-H Luke, J K M Wu, K Gill,[...]. J Thromb Haemost 2006
192
9

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, Atsushi Muto, Tetsuo Kojima, Tetsuhiro Soeda, Kazutaka Yoshihashi, Yukiko Okuyama-Nishida, Hiroyuki Saito, Hiroyuki Tsunoda,[...]. Nat Med 2012
260
9



Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Amit C Nathwani, Ulreke M Reiss, Edward G D Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj,[...]. N Engl J Med 2014
744
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.